Table 1 Baseline patient demographic details in Study 1222.6
Placebo (n = 54) | Olodaterol 2 μg (n = 61) | Olodaterol 5 μg (n = 60) | Olodaterol 10 μg (n = 60) | Olodaterol 20 μg (n = 61) | |
|---|---|---|---|---|---|
Age, mean (SD), years | 43.6 (14.1) | 45.4 (15.1) | 46.2 (13.0) | 46.3 (14.5) | 44.6 (13.0) |
Male, n (%) | 20 (37.0) | 22 (36.1) | 30 (50.0) | 26 (43.3) | 28 (45.9) |
Asthma diagnosis, mean (SD), years | 23.7 (13.3) | 19.8 (13.8) | 23.3 (15.6) | 22.5 (15.5) | 22.9 (16.2) |
Body mass index, mean (SD), kg/m2 | 28.6 (7.2) | 27.0 (6.1) | 28.8 (6.85) | 26.5 (5.2) | 27.3 (5.81) |
Smoking status, n (%) | |||||
Current smoker | 3 (5.6) | 7 (11.5) | 2 (3.3) | 2 (3.3) | 2 (3.3) |
Ex-smoker | 10 (18.5) | 16 (26.2) | 10 (16.7) | 14 (23.3) | 15 (24.6) |
Never smoker | 41 (75.9) | 38 (62.3) | 48 (80.0) | 44 (73.3) | 44 (72.1) |
Smoking history, mean (SD), pack-yearsa | 3.6 (2.4) | 4.8 (2.7) | 5.5 (2.8) | 5.9 (2.7) | 3.4 (2.6) |
Pre-bronchodilator FEV1, mean (SD), L | 2.30 (0.62) | 2.31 (0.74) | 2.39 (0.61) | 2.32 (0.64) | 2.37 (0.60) |
Post-bronchodilator FEV1, mean (SD), L | 2.72 (0.70) | 2.76 (0.91) | 2.79 (0.70) | 2.74 (0.70) | 2.82 (0.69) |
Change in FEV1 from pre-bronchodilator (SD), L | 0.43 (0.15) | 0.44 (0.23) | 0.41 (0.13) | 0.42 (0.16) | 0.44 (0.15) |
Post-bronchodilator FEV1:FVC ratio, mean (SD), % | 74.3 (7.4) | 75.1 (9.5) | 74.2 (7.2) | 73.6 (8.5) | 74.3 (7.4) |